New insights into the androgen biotransformation in prostate cancer: A regulatory network among androgen, androgen receptors and UGTs

Pharmacological Research

Volumn 106, Issue , 2016, Pages 114-122

  Qin, Xuan ^a   Liu, Mingyao ^a,b   Wang, Xin ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Androgen; Androgen receptors; Biotransformation; Prostate cancer; UDP glucuronyltransferases

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTERONE; BICALUTAMIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; FARNESOID X RECEPTOR; FINASTERIDE; FLUTAMIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; GOSERELIN; LEUPRORELIN; ORTERONEL; PRASTERONE; PREGNANE X RECEPTOR; SULFOTRANSFERASE; SULFOTRANSFERASE 2A1; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE TYPE ALOPECIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BIOTRANSFORMATION; MALE; METABOLISM; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR;

ANDROGENS; ANIMALS; BIOTRANSFORMATION; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84959463082     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.02.021     Document Type: Review

References (92)

1. E.E. Oldridge, D. Pellacani, A.T. Collins, and N.J. Maitland Prostate cancer stem cells: are they androgen-responsive? Mol. Cell. Endocrinol. 360 2012 14 24
2. S.B. Frank, and C.K. Miranti Disruption of prostate epithelial differentiation pathways and prostate cancer development Front. Oncol. 3 2013 273
3. K.J. Pienta, and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer Clin. Cancer Res. 12 2006 1665 1671
4. E.M. Kwon, S.K. Holt, R. Fu, S. Kolb, G. Williams, J.L. Stanford, and et al. Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk Cancer Epidemiol. 36 2012 347 353
5. Z. Guo, and Y. Qiu A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int. J. Biol. Sci. 7 2011 815 822
6. F. Labrie, A. Belanger, L. Cusan, and B. Candas Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology J. Clin. Endocrinol. Metab. 82 1997 2403 2409
7. T.M. Penning Androgen biosynthesis in castration-resistant prostate cancer Endocr. Relat. Cancer 21 2014 T67 78
8. L. Grosse, S. Paquet, P. Caron, L. Fazli, P.S. Rennie, A. Belanger, and et al. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications Cancer Res. 73 2013 6963 6971
9. O. Hiort The differential role of androgens in early human sex development BMC Med. 11 2013 152
10. P. Kempna, N. Marti, S. Udhane, and C.E. Fluck Regulation of androgen biosynthesis- A short review and preliminary results from the hyperandrogenic starvation NCI-H295R cell model Mol. Cell. Endocrinol. 408 2015 124 132
11. F. Saad, and L. Gooren The role of testosterone in the metabolic syndrome: a review J. Steroid Biochem. Mol. Biol. 114 2009 40 43
12. K.H. Chang, C.E. Ercole, and N. Sharifi Androgen metabolism in prostate cancer: From molecular mechanisms to clinical consequences Br. J. Cancer 111 2014 1249 1254
13. J.W. White I. The results of double castration in hypertrophy of the prostate Ann. Surg. 22 1895 1 80
14. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, and et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
15. X. Zhang, C. Morrissey, S. Sun, M. Ketchandji, P.S. Nelson, L.D. True, and et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases PLoS One 6 2011 e27970
16. N. Mitsiades, C.C. Sung, N. Schultz, D.C. Danila, B. He, V.K. Eedunuri, and et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors Cancer Res. 72 2012 6142 6152
17. Y. Shi, S.J. Chatterjee, F.H. Brands, S.R. Shi, L. Pootrakul, C.R. Taylor, and et al. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations BJU Int. 97 2006 170 178
18. J. Edwards, N.S. Krishna, R. Mukherjee, A.D. Watters, M.A. Underwood, and J.M. Bartlett Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer BJU Int. 88 2001 633 637
19. B. Le, H. Chen, B. Zirkin, and A. Burnett New targets for increasing endogenous testosterone production: Clinical implications and review of the literature Andrology 2 2014 484 490
20. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, and et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 66 2006 2815 2825
21. F. Labrie Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology J. Steroid Biochem. Mol. Biol. 145 2015 144 156
22. M. Olsson, L. Ekstrom, C. Guillemette, A. Belanger, A. Rane, and O. Gustafsson Correlation between circulatory, local prostatic, and intra-prostatic androgen levels Prostate 71 2011 909 914
23. O. Barbier, and A. Belanger Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate Best Pract. Res. Clin. Endocrinol. Metab. 22 2008 259 270
24. S. Chouinard, G. Pelletier, A. Belanger, and O. Barbier Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium Endocr. Res. 30 2004 717 725
25. T.M. Penning, Y. Jin, S. Steckelbroeck, T. Lanisnik Rizner, and M. Lewis Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: Genes and proteins Mol. Cell. Endocrinol. 215 2004 63 72
26. Q. Cheng, C.D. Sohl, F.K. Yoshimoto, and F.P. Guengerich Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4 J. Biol. Chem. 287 2012 29554 29567
27. R. Sirianni, B.A. Mayhew, B.R. Carr, C.R. Parker Jr., and W.E. Rainey Corticotropin-releasing hormone (CRH) and urocortin act through type 1CRH receptors to stimulate dehydroepiandrosterone sulfate production in human fetal adrenal cells J. Clin. Endocrinol. Metab. 90 2005 5393 5400
28. C.A. Ihunnah, M. Jiang, and W. Xie Nuclear receptor PXR, transcriptional circuits and metabolic relevance Biochim. Biophys. Acta 1812 2011 956 963
29. S. Chouinard, M.F. Yueh, R.H. Tukey, F. Giton, J. Fiet, G. Pelletier, and et al. Inactivation by UDP-glucuronosyltransferase enzymes: The end of androgen signaling J. Steroid Biochem. Mol. Biol. 109 2008 247 253
30. S. Leskela, E. Honrado, C. Montero-Conde, I. Landa, A. Cascon, R. Leton, and et al. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer Endocr. Relat. Cancer 14 2007 645 654
31. S. Chouinard, O. Barbier, and A. Belanger UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells J. Biol. Chem. 282 2007 33466 33474
32. ®), Prostate Cancer, Version I, 2015 2015 National Comprehensive Cancer Network Fort Washington (www.nccn.org/professionals/physician-gls/pdf/prostate.pdf) (accessed 14.10.2014)
33. R. Dreicer, D. MacLean, A. Suri, W.M. Stadler, D. Shevrin, L. Hart, and et al. Phase I/II trial of orteronel (TAK-700)-an investigational 17,20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer Clin. Cancer Res. 20 2014 1335 1344
34. ® (abiraterone Acetate) Tablets 2012 U.S. Food and Drug Administration FDA: Silver Spring (http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202379s005lbl.pdf) (accessed December, 2012)
35. G. Attard, J. Richards, and J.S. de Bono New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway Clin. Cancer Res. 17 2011 1649 1657
36. E.A. Mostaghel, B.T. Marck, S.R. Plymate, R.L. Vessella, S. Balk, A.M. Matsumoto, and et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants Clin. Cancer Res. 17 2011 5913 5925
37. E.S. Antonarakis, C. Lu, H. Wang, B. Luber, M. Nakazawa, J.C. Roeser, and et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N. Engl. J. Med. 371 2014 1028 1038
38. S. Giacinti, M. Bassanelli, A.M. Aschelter, A. Milano, M. Roberto, and P. Marchetti Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature Anticancer Res. 34 2014 6265 6269
39. T. Kaku, T. Hitaka, A. Ojida, N. Matsunaga, M. Adachi, T. Tanaka, and et al. Discovery of orteronel (TAK-700) a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorg. Med. Chem. 19 2011 6383 6399
40. M. Yamaoka, T. Hara, T. Hitaka, T. Kaku, T. Takeuchi, J. Takahashi, and et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys J. Steroid Biochem. Mol. Biol. 129 2012 115 128
41. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial) Clin. Adv. Hematol. Oncol. 12 2014 6 7
42. J. Azzarello, K.M. Fung, and H.K. Lin Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system J. Histochem. Cytochem. 56 2008 853 861
43. H.K. Lin, J.M. Jez, B.P. Schlegel, D.M. Peehl, J.A. Pachter, and T.M. Penning Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: Demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution Mol. Endocrinol. 11 1997 1971 1984
44. A.O. Adeniji, M. Chen, and T.M. Penning AKR1C3 as a target in castrate resistant prostate cancer J. Steroid Biochem. Mol. Biol. 137 2013 136 149
45. Y. Wu, A. Godoy, F. Azzouni, J.H. Wilton, C. Ip, and J.L. Mohler Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5-alpha-reductase inhibitors Prostate 73 2013 1470 1482
46. F. Azzouni, A. Godoy, Y. Li, and J. Mohler The 5-alpha-reductase isozyme family: a review of basic biology and their role in human diseases Adv. Urol. 2012 2012 530121
47. A. Godoy, E. Kawinski, Y. Li, D. Oka, B. Alexiev, F. Azzouni, and et al. 5-Alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression Prostate 71 2011 1033 1046
48. ® 2012 U.S. Food and Drug Administration FDA: Silver Spring (http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/020788Orig1s022lbl.pdf) (accessed June 17.06.2011)
49. AVODART (dutasteride) Soft Gelatin Capsules 2012 U.S. Food and Drug Administration FDA: Silver Spring (http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021319s028s029lbl.pdf) (accessed October, 2012)
50. A. Rowland, J.O. Miners, and P.I. Mackenzie The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification Int. J. Biochem. Cell Biol. 45 2013 1121 1132
51. R. Meech, J.O. Miners, B.C. Lewis, and P.I. Mackenzie The glycosidation of xenobiotics and endogenous compounds: Versatility and redundancy in the UDP glycosyltransferase superfamily Pharmacol. Ther. 134 2012 200 218
52. T.K. Kiang, M.H. Ensom, and T.K. Chang UDP-glucuronosyltransferases and clinical drug-drug interactions Pharmacol. Ther. 106 2005 97 132
53. S. Ohno, and S. Nakajin Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction Drug Metab. Dispos. 37 2009 32 40
54. M.H. Court, X. Zhang, X. Ding, K.K. Yee, L.M. Hesse, and M. Finel Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues Xenobiotica 42 2012 266 277
55. P.J. O'Shaughnessy, A. Monteiro, S. Bhattacharya, M.J. Fraser, and P.A. Fowler Steroidogenic enzyme expression in the human fetal liver and potential role in the endocrinology of pregnancy Mol. Hum. Reprod. 19 2012 177 187
56. R. Meech, A. Rogers, L. Zhuang, B.C. Lewis, J.O. Miners, and P.I. Mackenzie Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes J. Biol. Chem. 287 2012 24122 24130
57. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, T. Iyanagi, and et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily Pharmacogenet. Genomics 15 2005 677 685
58. T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, M. Takamiya, and et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers Drug Metab. Dispos. 37 2009 1759 1768
59. N. Sneitz, K. Krishnan, D.F. Covey, and M. Finel Glucuronidation of the steroid enantiomers ent-17beta-estradiol, ent-androsterone and ent-etiocholanolone by the human UDP-glucuronosyltransferases J. Steroid Biochem. Mol. Biol. 127 2011 282 288
60. D.W. Hum, A. Belanger, E. Levesque, O. Barbier, M. Beaulieu, C. Albert, and et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones J. Steroid Biochem. Mol. Biol. 69 1999 413 423
61. A. Belanger, G. Pelletier, F. Labrie, O. Barbier, and S. Chouinard Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans Trends Endocrinol. Metab. 14 2003 473 479
62. E. Strahm, U. Sjoberg, M. Garle, A. Rane, and L. Ekstrom Implication of human UGT2B7 2B15, and 2B17 in 19-norandrosterone metabolism Front Endocrinol. (Lausanne) 4 2013 75
63. D. Turgeon, J.S. Carrier, E. Levesque, D.W. Hum, and A. Belanger Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members Endocrinology 142 2001 778 787
64. S. Ohno, and S. Nakajin Quantitative analysis of UGT2B28 mRNA expression by real-time RT-PCR and application to human tissue distribution study Drug Metab. Lett. 5 2011 202 208
65. J. Geller Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer Semin. Oncol. 12 1985 28 35
66. F. Labrie Blockade of testicular and adrenal androgens in prostate cancer treatment Nat. Rev. Urol. 8 2011 73 85
67. O. Barbier, H. Lapointe, M. El Alfy, D.W. Hum, and A. Belanger Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry J. Clin. Endocrinol. Metab. 85 2000 4819 4826
68. B.Y. Bao, B.F. Chuang, Q. Wang, O. Sartor, S.P. Balk, M. Brown, and et al. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes Prostate 68 2008 839 848
69. S. Chouinard, G. Pelletier, A. Belanger, and O. Barbier Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: Differential consequences for androgen and bioactive lipid inactivation Endocrinology 147 2006 5431 5442
70. M. Beaulieu, E. Levesque, A. Tchernof, B.G. Beatty, A. Belanger, and D.W. Hum Chromosomal localization, structure, and regulation of the UGT2B17 gene encoding a C19 steroid metabolizing enzyme DNA Cell Biol. 16 1997 1143 1154
71. S. Paquet, L. Fazli, L. Grosse, M. Verreault, B. Tetu, P.S. Rennie, and et al. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression J. Clin. Endocrinol. Metab. 97 2012 E428 432
72. R. Hu, T.A. Dunn, S. Wei, S. Isharwal, R.W. Veltri, E. Humphreys, and et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res. 69 2009 16 22
73. F. Sun, H.G. Chen, W. Li, X. Yang, X. Wang, R. Jiang, and et al. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors J. Biol. Chem. 289 2014 1529 1539
74. S. Haile, and M.D. Sadar Androgen receptor and its splice variants in prostate cancer Cell Mol. Life Sci. 68 2011 3971 3981
75. L.L. Liu, N. Xie, S. Sun, S. Plymate, E. Mostaghel, and X. Dong Mechanisms of the androgen receptor splicing in prostate cancer cells Oncogene 33 2014 3140 3150
76. P.K. Manchanda, A.J. Kibler, M. Zhang, J. Ravi, and H.K. Bid Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia Indian J. Urol. 28 2012 377 381
77. W.L. Wang, M. Tenniswood, and D. Vitamin Intermediary metabolism and prostate cancer tumor progression Front. Physiol. 5 2014 183
78. S. Swami, A.V. Krishnan, and D. Feldman Vitamin D metabolism and action in the prostate: Implications for health and disease Mol. Cell. Endocrinol. 347 2011 61 69
79. J. Kaeding, J. Belanger, P. Caron, M. Verreault, A. Belanger, and O. Barbier Calcitrol (1-alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells Mol. Cancer Ther. 7 2008 380 390
80. D. Doherty, S.A. Dvorkin, E.P. Rodriguez, and P.D. Thompson V itamin D receptor agonist EB1089 is a potent regulator of prostatic intracrine metabolism Prostate 74 2014 273 285
81. J. Kaeding, E. Bouchaert, J. Belanger, P. Caron, S. Chouinard, M. Verreault, and et al. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells Biochem. J. 410 2008 245 253
82. M. Baptissart, A. Vega, E. Martinot, S. Baron, J.M. Lobaccaro, and D.H. Volle Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling? Cell. Mol. Life Sci. 70 2013 4511 4526
83. R.M. Gadaleta, M. Cariello, C. Sabba, and A. Moschetta Tissue-specific actions of FXR in metabolism and cancer Biochim. Biophys. Acta 1851 2015 30 39
84. J. Liu, S.J. Tong, X. Wang, and L.X. Qu Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN Exp. Ther. Med. 8 2014 1209 1212
85. J. Jakobsson, L. Ekstrom, N. Inotsume, M. Garle, M. Lorentzon, C. Ohlsson, and et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism J. Clin. Endocrinol. Metab. 91 2006 687 693
86. J. Park, L. Chen, L. Ratnashinge, T.A. Sellers, J.P. Tanner, J.H. Lee, and et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men Cancer Epidemiol. Biomarkers Prev. 15 2006 1473 1478
87. A.H. Karypidis, M. Olsson, S.O. Andersson, A. Rane, and L. Ekstrom Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate Pharmacogenomics J. 8 2008 147 151
88. G. Nadeau, J. Bellemare, E. Audet-Walsh, C. Flageole, S.P. Huang, B.Y. Bao, and et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer J. Clin. Endocrinol. Metab. 96 2011 E1550 1557
89. L. Cai, W. Huang, and K.C. Chou Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis Protein Pept. Lett. 19 2012 62 69
90. C.J. Gallagher, F.F. Kadlubar, J.E. Muscat, C.B. Ambrosone, N.P. Lang, and P. Lazarus The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians Cancer Detect. Prev. 31 2007 310 315
91. M. Olsson, S. Lindstrom, B. Haggkvist, H.O. Adami, K. Balter, P. Stattin, and et al. The UGT2B17 gene deletion is not associated with prostate cancer risk Prostate 68 2008 571 575
92. L. Gauthier-Landry, A. Belanger, and O. Barbier Multiple roles for udp-glucuronosyltransferase (UGT) 2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution J. Steroid Biochem. Mol. Biol. 2015 187 192